Increased incidence of Parkinson disease among relatives of patients with Gaucher disease

Blood Cells, Molecules, and Diseases

Volumn 36, Issue 3, 2006, Pages 426-428

  Halperin, Assaf ^a   Elstein, Deborah ^a   Zimran, Ari ^a  

^a SHAARE ZEDEK MEDICAL CENTER   (Israel)

Author keywords

Gaucher disease; Obligate carrier; Parkinson disease

Indexed keywords

ARTICLE; CONTROLLED STUDY; GAUCHER DISEASE; HUMAN; INCIDENCE; JEW; PARKINSON DISEASE; PRIORITY JOURNAL; QUESTIONNAIRE; SEX DIFFERENCE;

COHORT STUDIES; FAMILY; FEMALE; GAUCHER DISEASE; HETEROZYGOTE; HUMANS; INCIDENCE; ISRAEL; JEWS; MALE; MUTATION; PARKINSON DISEASE; QUESTIONNAIRES;

EID: 33646837867     PISSN: 10799796     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcmd.2006.02.004     Document Type: Article

References (19)

1. Beutler E., and Grabowski G.A. Gaucher disease. In: Scriver C.R., Valle D., Beudet A., and Sly W.S. (Eds). The Metabolic and Molecular Bases of Inherited Diseases (2001), McGraw-Hill, New York 3635-3668 (III)
2. O. Neudorfer, MD Thesis: occurrence of parkinsonianism among patients and carriers of type I Gaucher disease. Hebrew University-Hadassah Medical School, 1994.
3. Neudorfer O., Giladi N., Elstein D., Abrahamov A., Turezkite T., Aghai E., Reches A., Bembi B., and Zimran A. Occurrence of Parkinson's syndrome in type I Gaucher disease. QJM 89 (1996) 691-694
4. Machaczka M., Rucinska M., Skotnicki A.B., and Jurczak W. Parkinson's syndrome preceding clinical manifestation of Gaucher's disease. Am. J. Hematol. 61 (1999) 216-217
5. Varkonyi J., Simon Z., and Soos K. Poros A Gaucher disease type I complicated with Parkinson's syndrome. Haematologia (Budap) 32 (2002) 271-275
6. Bembi B., Zambito Marsala S., Sidransky E., Ciana G., Carrozzi M., Zorzon M., Martini C., Gioulis M., Pittis M.G., and Capus L. Gaucher's disease with Parkinson's disease: clinical and pathological aspects. Neurology 61 (2003) 99-101
7. Lwin A., Orvisky E., Goker-Alpan O., LaMarca M.E., and Sidransky E. Glucocerebrosidase mutations in subjects with parkinsonism. Mol. Genet. Metab. 81 (2004) 70-73
8. Clark L.N., Nicolai A., Afridi S., Harris J., Mejia-Santana H., Strug L., Cote L.J., Louis E.D., Andrews H., Waters C., Ford B., Frucht S., Fahn S., Mayeux R., Ottman R., and Marder K. Pilot association study of the beta-glucocerebrosidase N370S allele and Parkinson's disease in subjects of Jewish ethnicity. Mov. Disord. 20 1 (2005) 100-103
9. Goker-Alpan O., Schiffmann R., LaMarca M.E., Nussbaum R.L., McInerney-Leo A., and Sidransky E. Parkinsonism among Gaucher disease carriers. J. Med. Genet. 41 (2004) 9340-9379
10. Aharon-Peretz J., Rosenbaum H., and Gershoni-Baruch R. Mutations in the glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews. N. Engl. J. Med. 351 (2004) 1972-1977
11. Sidransky E. Gaucher disease: complexity in a "simple" disorder. Mol. Genet. Metab. 83 (2004) 6-15
12. Tayebi N., Callahan M., Madike V., Stubblefield B.K., Orvisky E., Krasnewich D., Fillano J.J., and Sidransky E. Gaucher disease and parkinsonism: a phenotypic and genotypic characterization. Mol. Genet. Metab. 73 (2001) 313-321
13. Tayebi N., Walker J., Stubblefield B., Orvisky E., LaMarca M.E., Wong K., Rosenbaum H., Schiffmann R., Bembi B., and Sidransky E. Gaucher disease with parkinsonian manifestations: does glucocerebrosidase deficiency contribute to a vulnerability to parkinsonism?. Mol. Genet. Metab. 79 (2003) 104-109
14. Wong K., Sidransky E., Verma A., Mixon T., Sandberg G.D., Wakefield L.K., Morrison A., Lwin A., Colegial C., Allman J.M., and Schiffmann R. Neuropathology provides clues to the pathophysiology of Gaucher disease. Mol. Genet. Metab. 82 (2004) 192-207
15. Logroscino G. The role of early life environmental risk factors in Parkinson disease: what is the evidence?. Environ. Health Perspect. 113 (2005) 1234-1238
16. Brown R.C., Lockwood A.H., and Sonawane B.R. Neurodegenerative diseases: an overview of environmental risk factors. Environ. Health Perspect. 113 (2005) 1250-1256
17. Butters T.D., Mellor H.R., Narita K., Dwek R.A., and Platt F.M. Small-molecule therapeutics for the treatment of glycolipid lysosomal storage disorders. Philos. Trans. R. Soc. Lond., B Biol. Sci. 358 (2003) 927-945
18. Zimran A., and Elstein D. Gaucher disease and the clinical experience with substrate reduction therapy. Philos. Trans. R. Soc. Lond., B Biol. Sci. 358 (2003) 961-966
19. Alfonso P., Pampin S., Estrada J., Rodriguez-Rey J.C., Giraldo P., Sancho J., and Pocovi M. Miglustat (NB-DNJ) works as a chaperone for mutated acid beta-glucosidase in cells transfected with several Gaucher disease mutations. Blood Cells Mol. Diseases 35 (2005) 268-276